Endocyte Bullish on Potential Blockbuster

Posted: Updated:
(image courtesy of Endocyte) Mike Sherman previously served as chief financial officer and helped the company transition to being publicly-traded. (image courtesy of Endocyte) Mike Sherman previously served as chief financial officer and helped the company transition to being publicly-traded.
WEST LAFAYETTE -

The chief executive officer of West Lafayette-based Endocyte Inc. (Nasdaq: ECYT) is using a word to describe the company's $12 million worldwide licensing acquisition of a late-stage prostate cancer therapy that he says is often overused: transformational. "In this case, the word is absolutely fitting," said Mike Sherman during a conference call with investors detailing the deal with Germany-based ABX GmbH. Endocyte has been working to reverse a series of quarterly losses in recent years, including a major restructuring and work force reduction announced in June.

Sherman has an ambitious timeline for PSMA-617, which he says could begin the clinical trial process early next year and complete trial stages as early as 2020. "Our experience with PSMA targeting and companion imaging development, in addition to our relationships with distinguished prostate cancer investigators from around the world, uniquely position Endocyte to lead this therapy to registration," Sherman said in a statement. During Monday's conference call, he added the therapy, if it meets approvals, would position Endocyte in a leading position in a $1 billion prostate cancer-fighting market.

Sherman and Chief Medical Officer Alison Armour say the high potential of the prostate-specific membrane antigen presents a rare opportunity. "Despite advances in the last decade that slow the progression of prostate cancer, once metastasized it is nearly always lethal, leading to 300,000 worldwide deaths annually," said Armour. "177Lu-PSMA-617 has demonstrated the most compelling activity of any drug currently in development for these post-chemotherapy patients."

Aside from a "very targeted" proof-of-concept data effort for the company's CAR T-cell program, Sherman says Endocyte's resources will be focused on developing the promising prostate cancer therapy. Additionally, "we will explore out-licensing opportunities for all other development programs," he said.

Down the line, Sherman says Endocyte has an opportunity to develop a pipeline of similar therapies that target other deadly diseases. He has served in c-level roles with the company for the last 11 years and in mid-2016, succeeded co-founder Ron Ellis as president and CEO.

Mike Sherman has an ambitious timeline for PSMA-617, which he says could begin the clinical trial process early next year and complete trial stages as early as 2020.
  • Perspectives

    • The Evolution of Business: From Bottom Line to Value Creation And Impact

      In today's world, consumers want to know how corporations, as a whole, are taking a stand. In fact, customers are 43 percent more likely to purchase a product from a company they know is committed to social value. It's not just consumers pushing this trend. Financial service industry leaders, like KeyBank's Beth Mooney and BlackRock's Larry Fink, are challenging business owners and the C-Suite to rethink their economic impact, environmental footprint and social conscience.

    More

Subscribe

Name:
Company Name:
Email:
Confirm Email:
HTML
INside Edge
Morning Briefing
BigWigs & New Gigs
Life Sciences Indiana
Indiana Connections
INPower
Subscribe
Unsubscribe

Events



  • Most Popular Stories

    • St. Vincent Announces Layoffs

      St. Vincent Health says it has laid off 85 employees throughout the state. In a statement to Inside INdiana Business, St. Vincent cites a rapidly-evolving healthcare environment as a reason for the workforce reduction. 

    • GM recently announced it would invest more than $1 billion in its Fort Wayne Assembly plant.

      Auto Job Fair Coming to Allen County

      General Motors is hiring more than 100 new employees in Fort Wayne. The positions in everything from finance to manufacturing are following a gradually increasing presence in the area for the past few years. In 2016, the company invested $127 million in its casting plant in Bedford and planned to pump an additional $1 billion into the Fort Wayne area over the next few years to double the size of its operation. The expansion of GM’s operations has led to increased business for ...

    • Indy Firm Taps Appirio Exec as CEO

      An Indianapolis-based design and innovation consulting firm has named a new chief executive officer. Studio Science says Steve Pruden, who most recently served as senior vice president of human resources with Indy tech company Appirio, will lead the company.

    • Rose-Hulman Adds New Major

      Rose-Hulman Institute of Technology students now have another option when choosing a major. The Institute has added a engineering design major which is expected to offer a multidisciplinary experience. Students are enrolled to start the new program in the 2018-2019 school year. 

    • (Image Courtesy: Lilly Oncology)

      Lilly Closes on Mega Acquisition

      Indianapolis-based Eli Lilly and Co. (NYSE: LLY) has completed its acquisition of ARMO BioSciences Inc. of California. The deal, which was valued at approximately $1.6 billion when first announced last month, boosts Lilly's immuno-oncology pipeline. Lilly offered $50 per share of ARMO stock for the company. ARMO's portfolio includes...